BeyondSpring Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on cancer therapies, including Plinabulin development, financial results and capital structure. Its Form 10-K and Form 8-K disclosures cover audited consolidated financial statements, quarterly and annual operating results, clinical-program updates, and risk and business information tied to oncology development.
Current reports also record material agreements, registered offerings of ordinary shares, SEED Therapeutics financing and ownership disclosures, and shareholder-vote results from annual meetings. These filings describe governance actions, securities issuances, registration-statement use and other material events affecting BeyondSpring’s public-company reporting.
BeyondSpring Inc. reported a consolidated net loss of $6.7 million for the three months ended March 31, 2026, compared with net income of $1.2 million a year earlier, when results were boosted by a $7.0 million gain on a SEED share sale.
Continuing operations posted a net loss of $2.4 million as research and development expenses rose to $1.1 million and general and administrative costs declined to $1.2 million. Discontinued SEED operations generated a loss of $4.3 million, reflecting ongoing investment in its targeted protein degradation platform.
Cash and cash equivalents plus short-term investments from continuing operations totaled $7.9 million as of March 31, 2026, while deferred revenue of about $29.0 million from the Hengrui collaboration remained on the balance sheet. Management expects additional cash inflows from staged sales of SEED preferred shares and is evaluating financing and strategic alternatives.
BeyondSpring Inc. reported first-quarter 2026 results showing a shift from profit to loss while advancing its oncology pipeline. Net loss was $6.7 million for the quarter ended March 31, 2026, compared with net income of $1.2 million a year earlier, driven mainly by losses in discontinued operations.
From continuing operations, net loss narrowed slightly to $2.4 million from $2.6 million as research and development expenses rose to $1.1 million and general and administrative costs fell to $1.1 million. Cash, cash equivalents, and short-term investments totaled $7.9 million as of March 31, 2026, with shareholders’ deficit at $30.4 million.
Strategically, BeyondSpring highlighted new preclinical data suggesting its lead asset Plinabulin may enhance efficacy and tolerability of antibody-drug conjugate regimens, and announced that SEED Therapeutics advanced RBM39 molecular glue degrader ST-01156 into Phase 1 clinical development using a biomarker-driven approach.
BeyondSpring Inc. director Matthew Kirkby received a grant of stock options covering 23,902 ordinary shares. The options have an exercise price of $1.64 per share and expire on April 1, 2036. All options vest on April 1, 2027, contingent on his continuous service with the company.
BeyondSpring Inc. director Patrick Fabbio received a grant of stock options covering 22,165 ordinary shares. The options have an exercise price of $1.64 per share and were issued under the company’s 2017 Omnibus Incentive Plan as part of his compensation.
All 22,165 options vest on April 1, 2027, provided he continues serving the company through that date, and they expire on April 1, 2036. This is a compensation-related award, not an open-market purchase or sale of BeyondSpring shares.
BeyondSpring Inc. director Brendan Delaney received a grant of stock options for 20,427 ordinary shares on April 1, 2026 as equity compensation. The options have an exercise price of $1.64 per share and expire on April 1, 2036. All options vest on April 1, 2027, subject to his continuous service with the company through that date.
BeyondSpring Inc. director Majeti Jiangwen received a grant of stock options to purchase 21,730 Ordinary Shares of the company. These options have an exercise price of $1.64 per share and expire on April 1, 2036.
All of the options will vest on April 1, 2027, provided the director continues to serve the company through that date. Following this grant, the Form 4 shows holdings of 21,730 stock options directly owned.
BeyondSpring Inc. reported that Chief Scientific Officer Lu Yingjuan June received a grant of stock options for 17,840 ordinary shares. The options have an exercise price of $1.64 per share and expire on April 1, 2036.
According to the grant terms, 4,460 options will vest on each of April 1, 2027, April 1, 2028, April 1, 2029 and April 1, 2030, as long as she continues serving the company through those dates. All options were reported as directly owned following this award.
BeyondSpring Inc. director and Chief Executive Officer Huang Lan received a grant of stock options to acquire 11,514 Ordinary Shares. The options have an exercise price of $1.804 per share and were awarded at no cost to the reporting person.
According to the grant terms, 2,878 options will vest on each of April 1, 2027, April 1, 2028 and April 1, 2029, and 2,880 options will vest on April 1, 2030, subject to continuous service with the company. The options expire on April 1, 2031. This is a compensation-related award rather than an open-market purchase or sale.
Xu Sihai reported acquisition or exercise transactions in this Form 4 filing.
BeyondSpring Inc. director Xu Sihai received a grant of stock options covering 18,689 ordinary shares. The options have a strike price of $1.64 per share and expire on April 1, 2036.
According to the grant terms, all of these stock options vest on April 1, 2027, provided Xu continues to serve with the company through that date. This award increases his directly held derivative position to 18,689 options and reflects compensation rather than an open-market purchase or sale.
BeyondSpring Inc. reports another year of operating losses as it advances its oncology pipeline. The company generated no revenue in 2025 and recorded a consolidated net loss of $14.2 million, narrowing from $16.7 million in 2024, with losses driven by research and development and general and administrative expenses.
Cash and cash equivalents from continuing operations were $7.8 million as of December 31, 2025, while net cash used in operating activities increased to $19.8 million. The balance sheet shows total assets of $25.9 million against total liabilities of $49.9 million, resulting in a shareholders’ deficit of $24.0 million.
BeyondSpring continues to focus on Plinabulin, a first-in-class small molecule for non-small cell lung cancer and other cancers, supported by positive Phase 3 data (DUBLIN-3) and multiple investigator-initiated trials. It also retains an equity stake in SEED Therapeutics, which is advancing a targeted protein degradation platform and has initiated a Phase 1 study of its RBM39 degrader.
Management states it expects ongoing losses and indicates that additional capital—through equity, debt, partnerships, or asset sales—will be required to fund development and operating needs, with potential dilution and other financing constraints highlighted as key risks.